Ann Rheum Dis. 2022 doi: 10.1136/annrheumdis-2021-221664
In this study Mease, et al. aimed to evaluate the efficacy and safety of deucravacitinib in patients with active PsA. Treatment with the selective TYK2i deucravacitinib was well tolerated and resulted in greater improvements than placebo in ACR-20 as well as Multiplicity-controlled secondary endpoints and other exploratory efficacy measures in patients.
researchers recruited 203 patients with active PsA, 15% of whom had failed previous biologic therapies, and randomised them into three groups: Placebo, Deucravacitinib 6 mg once a day, and Deucravacitinib 12 mg once a day. The primary end point was ACR-20 response at week 16.
This study highlighted significant clinical improvements in both deucravacitinib 6 mg and 12 mg QD compared with placebo. However, Larger trials over longer periods of time with deucravacitinib are warranted to confirm its safety profile and benefits in PsA.